Axitinib (Axitinib) medical insurance price in 2023

Axitinib (Axitinib) is a targeted therapy drug that belongs to a class of tyrosine kinase inhibitors and is mainly used to treat advanced renal cell carcinoma (RCC). The drug is unique in that it acts on vascular endothelial growth factor receptors (VEGFR), blocking angiogenesis and slowing tumor growth by inhibiting the activity of these receptors.

Axitinib has been launched in China and has been included in medical insurance. Patients can purchase it domestically. The price of 5mg*28 tablets is about 5,000 to 6,000 yuan. For specific prices, please consult the local hospital pharmacy. There are original and generic axitinib drugs abroad. The original drug is Pfizer's original drug, and the price is about 6,000 yuan; the generic drugs are mainly Bangladeshi generics and Indian generics. The price of Bangladeshi generics in 5mg*60 tablets is more than 1,000 yuan, and the price of Indian generics is around a few hundred yuan. The ingredients of original drugs and generic drugs are basically the same.

Renal cell carcinoma is a malignant tumor that originates in the cells within the tubules of the kidney. In advanced stages, renal cell carcinoma is often highly vascularized, making axitinib's targeting mechanism particularly important. By inhibiting VEGFR, axitinib can interfere with the tumor's supply of blood and nutrients, thereby preventing tumor growth and spread.

Axitinib is often used as an effective option for patients with advanced renal cell carcinoma when other treatment options are ineffective or unsuitable. Its oral administration feature enables patients to conveniently undergo treatment at home, improving patient convenience.

However, axitinib is not without side effects. During treatment, patients may experience adverse reactions such as high blood pressure, hand-foot syndrome (redness, swelling, pain in hands and feet, etc.), nausea, vomiting, fatigue, etc. Therefore, during the use of axitinib, patients need to be closely monitored and maintain regular communication with their doctors in order to adjust the treatment plan or provide corresponding support measures in a timely manner.